Shots:

• The P-III OSTRO study involves assessing of Fasenra (30mg- SC- q4w for first three doses and q8w thereafter) vs PBO in 413 patients with nasal polyposis who were still symptomatic despite continued treatment with SoC for 56wks. across EU and North America
• Results: Improvement in the size of nasal polyps and in nasal blockage in patients with CRSwNP- improvement in the endoscopic total NPS and the NBS- safety profile and tolerability of therapy were consistent with the known profile of the medicine
• Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the US- EU- Japan- and other countries and is approved for self-administration in the US- EU- and other countries

­ Ref: AstraZeneca | Image: EI Global